SOMA Research

BPC-157 and TB-500: A Research Guide to the Blend

BPC-157 with TB-500 is the most frequently paired combination in research-peptide catalogues, and the pairing is often explained badly. The two are not related molecules, they are not variants, and they do not share a pathway. They are combined because their literatures sit in two different domains that happen to be studied in the same models. This guide covers both compounds, what the blend format means analytically, and one naming ambiguity that affects every TB-500 purchase.

SOMA Research supplies this blend for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.

Two unrelated molecules

BPC-157 TB-500
Parent Body Protection Compound, a gastric juice protein Thymosin β4, a 43-residue protein
Length 15 amino acids 7 amino acids (as usually supplied)
Sequence GEPPPGKPADDAGLV LKKTETQ, usually N-acetylated
Molecular weight ~1,419.5 g/mol ~889 g/mol (acetylated heptapeptide)
Literature domain Angiogenic and nitric oxide signalling Actin binding and cell motility

The mechanistic distinction is the useful one. Thymosin β4’s best-characterised function is sequestering G-actin, which places its literature in the cytoskeletal and cell-migration domain. BPC-157’s literature sits in the vascular and signalling domain. A researcher using both is probing two pathways, not doubling one input. Our BPC-157 guide covers that compound in full, including the synthesis-impurity problem specific to its Asp-Asp motif.

“TB-500” is ambiguous, and it matters

This is the part worth reading before any purchase from any supplier.

Thymosin β4 is a 43-residue protein of roughly 4,960 g/mol. The actin-binding activity most of its literature concerns is associated with a short internal region, and the heptapeptide LKKTETQ — usually supplied N-acetylated, around 889 g/mol — is what is sold as “TB-500” in nearly all cases.

Those are not the same thing. One is a protein five and a half times the mass of the other. Yet the name “TB-500” is applied to both in circulation, and a great deal of secondary writing cites full-length thymosin β4 studies as though they characterised the heptapeptide.

Two consequences:

  • Check the mass on the CoA, not the product name. Roughly 889 means the acetylated heptapeptide. Roughly 4,960 means the full protein. The molecular weights are far enough apart that no mass spectrum is ambiguous about which you have.
  • Check which one a paper used before treating its findings as applicable. A fragment is not a guaranteed stand-in for the protein it came from, and whether the heptapeptide reproduces full-length behaviour is an open question in this literature rather than a settled one.

What the published research examines

BPC-157 — preclinical cell culture and rodent work on VEGFR2 signalling, nitric oxide pathway interaction, growth factor expression and gastrointestinal injury models. Largely from a small number of research groups, which limits independent replication.

Thymosin β4 and its fragments — actin sequestration, cell migration assays, and wound and tissue models in rodents. The full protein has a far larger and more independently replicated literature than the heptapeptide.

For both: no approved human indication, and no completed body of peer-reviewed human efficacy data establishing safety or effect. Commercial claims about human outcomes are not supported by this evidence base.

Reading a two-component CoA

A blend vial contains two molecules, and a certificate written for one does not describe it.

  • A single purity figure is ambiguous. It may describe each component separately or their combined peak area against everything else. A complete CoA resolves and reports each component.
  • Ratio is separate from purity. Both components can be individually pure and still be present in the wrong proportion. Purity says what fraction is not impurity; it says nothing about how much of each intended component is present.
  • Expect two masses. Roughly 1,419.5 and roughly 889. A single reported mass on a two-component blend is an incomplete report — and because the TB-500 figure also resolves the naming ambiguity above, it is the more informative of the two.
  • Separation should be clean here. A 15-residue peptide and a 7-residue peptide differ enough in hydrophobicity to resolve on a standard reversed-phase gradient. Confirm the two peaks are actually separated rather than assuming it.
  • Peptide content per component. Both are supplied as salts, so counter-ion contributes to weighed mass, and for the smaller peptide that contribution is proportionally larger.

Our Certificate of Analysis guide covers the fields in detail; measured figures per lot are in the CoA library.

Handling and storage

  • Lyophilised powder: -20°C, protected from light. Stable for 24 months or more.
  • Before opening: bring the vial to room temperature; both components are supplied as hygroscopic acetate salts.
  • Reconstituted stock: 2–8°C, aliquoted, used within approximately 30 days.
  • The ratio is fixed once reconstituted. Both components dissolve together and cannot be separated on a normal bench, so every aliquot carries the vial’s ratio. An experiment needing the components independently must source them independently — SOMA lists BPC-157 separately for that reason.
  • No oxidation-prone residues. Neither sequence contains methionine, cysteine or tryptophan, so the +16 Da failure mode common to other compounds does not apply.
  • Avoid freeze-thaw cycling.

Procedure and concentration arithmetic — which for a blend must be done per component — are in our reconstitution guide.

Research use only

Research-grade BPC-157 and TB-500 are supplied for laboratory use by qualified researchers and institutions. They are not manufactured to pharmaceutical standards, have not been approved by the FDA for any use, and must not be used in or on humans or animals. Nothing in this guide is medical advice or a representation that either compound is safe or effective for any purpose.